IRVINE, Calif., March 26, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergic medications, announced today that its Board of Directors has appointed a new Chairman and an additional member, effective February 1, 2004: Radul Radovich, former Project Manager at Ciba-Geigy, and Dr. Kevin Prendiville, CEO of Prendiville Eye Care Center in Phoenix, Arizona.
Radul "Rudy" Radovich has been appointed Chairman of the Board of BioGentech. His diverse experience led him to provide consulting services to several Fortune 100 corporations. Mr. Radovich was formerly the Senior Project Manager and Project Head for several projects with Ciba-Geigy (Novartis), British Petroleum, Parsons, Narmco, Page Engineering and others. Radovich has been Chairman of R & R Holdings, Inc., a private investment banking company, for over 15 years. He earned a MSME at University of Belgrade, Yugoslavia. Mr. Radovich is the father of BioGentech President Chaslav Radovich.
Kevin J. Prendiville, M.D., F.A.C.S., is a Diplomate of the American Board of Ophthalmology and a Fellow of the American College of Surgeons. Since 1986, he has run an ophthalmology practice in Cottonwood and Sedona, Arizona, specializing in small incision cataract surgery, cosmetic and functional eyelid surgery, as well as excimer laser vision correction. Dr. Prendiville also serves as Medical Director for the Cottonwood/Verde Valley Eye Surgery Center and, since 1989, has held numerous medical leadership positions at Verde Valley Medical Center in Cottonwood.
Chaslav Radovich, BioGentech's President and CEO, commented, "We are very fortunate to have these two professionals join our Board of Directors. They bring a unique background and a fresh perspective to the Company. We expect that Rudy's extensive knowledge and time spent in the pharmaceutical industry in combination with Kevin's experience in both the business and medical communities will aid us in the development of our corporate strategy."
About BioGentech Corp. - Prehistin(tm)
Headquartered in Irvine, California, BioGentech Corp. is an over-the-counter pharmaceutical company. Its flagship product, Prehistin(tm), designed to prevent the primary cause of airborne allergies, is scheduled for Phase III clinical trials in the fall of 2004 and initial marketing in the U.S. will commence upon final FDA marketing approval. The U.S. anti-allergy medication market was $7.2 billion in 2003 and is expected to exceed $10 billion by 2010. Prehistin, "the world's first pre-histamine," has shown in previous clinical studies to modulate the body's level of the protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Its active ingredient appears to have essentially no risks of adverse effects to the general population, including sedating and drowsiness found in many of the allergy products currently available.
For further information please visit the website at www.biogentec.com.
Safe Harbor
This news release includes statements that are not historical facts and are considered "forward-looking" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect BioGentech Corp's current views about future events. They are identified by their use of terms and phrases such as "believe," "expect," "plan," "anticipate", "possibility" and similar expressions identifying their forward-looking character. Investors should not rely on these forward-looking statements as assurances of future events, because such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from the Company's expectations. The factors that may affect the outcome of such expectations include, but are not limited to factors detailed from time to time in the Company's filings with the Securities and Exchange Commission.